Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/202625
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Santana Viera, Laura | - |
dc.contributor.author | Dassie, Justin P. | - |
dc.contributor.author | Rosàs Lapeña, Marta | - |
dc.contributor.author | Garcia Monclús, Silvia | - |
dc.contributor.author | Chicón Bosch, Mariona | - |
dc.contributor.author | Pérez Capó, Marina | - |
dc.contributor.author | Pozo, Lidia del | - |
dc.contributor.author | Sánchez Serra, Sara | - |
dc.contributor.author | Almacellas Rabaiget, Olga | - |
dc.contributor.author | Maqueda Marcos, Susana | - |
dc.contributor.author | López Alemany, Roser | - |
dc.contributor.author | Thiel, William H. | - |
dc.contributor.author | Giangrande, Paloma H. | - |
dc.contributor.author | Tirado, Oscar M. | - |
dc.date.accessioned | 2023-10-06T17:21:44Z | - |
dc.date.available | 2023-10-06T17:21:44Z | - |
dc.date.issued | 2023-05-08 | - |
dc.identifier.issn | 2162-2531 | - |
dc.identifier.uri | http://hdl.handle.net/2445/202625 | - |
dc.description.abstract | The EphA2 receptor tyrosine kinase is overexpressed in most solid tumors and acts as the major driver of tumorigenesis. In this study, we developed a novel approach for targeting the EphA2 receptor using a 20-fluoro-modified pyrimidine RNA aptamer termed ATOP. We identified the ATOP EphA2 aptamer using a novel bioinformatics strategy that compared aptamers enriched during a protein SELEX using recombinant human EphA2 and a cell-internalization SELEX using EphA2-expressing MDA231 tumor cells. When applied to EphA2-expressing tumor cell lines, the ATOP EphA2 aptamer attenuated tumor cell migration and clonogenicity. In a mouse model of spontaneous metastasis, the ATOP EphA2 aptamer slowed primary tumor growth and significantly reduced the number of lung metastases. The EphA2 ATOP aptamer represents a promising candidate for the development of next-generation targeted therapies that provide safer and more effective treatment of EphA2-overexpressing tumors. | - |
dc.format.extent | 15 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Elsevier BV | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1016/j.omtn.2023.05.003 | - |
dc.relation.ispartof | Molecular Therapy - Nucleic Acids, 2023, vol. 32, p. 758-772 | - |
dc.relation.uri | https://doi.org/10.1016/j.omtn.2023.05.003 | - |
dc.rights | cc by-nc-nd (c) Santana Viera, Laura et al., 2023 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Virus oncogènics | - |
dc.subject.classification | Terapèutica | - |
dc.subject.other | Oncogenic viruses | - |
dc.subject.other | Therapeutics | - |
dc.title | Combination of protein and cell internalization SELEX identifies a potential RNA therapeutic and delivery platform to treat EphA2-expressing tumors | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2023-09-22T10:47:16Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 37251690 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
PIIS2162253123001208.pdf | 3.86 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License